HygiBiome offers a path for innovation in the microbiome field and personal medicine.
Utilizing its HygiSample™ effluent during the HygiPrep® and HygiRelief® procedures, HygiBiome® provides access to real inner-colonic gut microbiome, that has been shown to be profoundly different than that of traditionally collected stool samples. With the increase in drug development costs and the search for reliable biomarkers to assist disease management, an analysis of an optimal sample provided by HygiBiome can represent the microbial and biochemical content of the colon lumen.
Hygieacare Inc. and HygiBiome® are ready to partner with medical and pharmaceutical collaborators to provide laboratory analyses and medical research services. Our services are aimed to help our partners promote development and implementation of novel solutions for wellness and nutrition for screening, diagnosis, disease prevention, personalized medicine, and drug development, as well as for surveillance, monitoring and reporting purposes.
To hear more about HygiBiome® and HygiSample™, please contact us at
“A non-invasive patented method to obtain unique inner-colonic microbiome”,
Orly Levitan PhD, Chief Scientist, Hygieacare at the Microbiome Movement Drug development EU summit, (a Hanson Wade conference), London, UK, Jan 2022
Orly Levitan, PhD, Chief Scientist, Hygieacare, Inc.
Speaker at the 8th Microbiome & Probiotics R&D and Business Collaboration Forum USA
During this challenging time of the COVID-19 pandemic, The health and safety of our patients and our staff is our highest priority at Hygieacare.
Following the guidance from public health authorities to limit the spread of COVID-19 for maintaining a safe environment, We have implemented multiple precautionary measures in the Hygieacare Centers.
We are grateful to the healthcare professionals on the front lines who are fighting to contain the virus and help patients with COVID-19.